10:25 AM EDT, 04/22/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our 12-month target price unchanged at $380 on a forward P/E of 29.1x our 2027 earnings estimate, a premium to the three-year historical average of 23.0x, given strong margins and fewer concerns surrounding competitive threats. We raise our 2026 EPS estimate to $12.48 from $11.79 and increase 2027's by $0.54 to $13.06. Our revenue projections are $7.1 billion and $7.5 billion, respectively. CME delivered record Q1 revenue, average daily volume, and earnings, demonstrating strong operational performance. The company is successfully navigating competitive pressures, and we anticipate margin expansion in 2026. AI threats are also not showing up as CME's market data and information services segment (13% of revenue) has posted accelerating growth for six consecutive quarters. Despite these strengths, including best-in-class margins and minimal AI risk, the stock trades below both peer multiples and CME's historical average on a forward P/E basis, creating an attractive buying opportunity.